X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2748) 2748
Book Review (518) 518
Publication (441) 441
Book Chapter (18) 18
Conference Proceeding (11) 11
Magazine Article (2) 2
Book / eBook (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2540) 2540
humans (2516) 2516
proto-oncogene proteins b-raf - antagonists & inhibitors (1518) 1518
proto-oncogene proteins b-raf - genetics (1417) 1417
oncology (1101) 1101
mutation (1054) 1054
melanoma (967) 967
animals (955) 955
melanoma - drug therapy (902) 902
cell line, tumor (822) 822
cancer (777) 777
female (745) 745
proto-oncogene proteins b-raf - metabolism (656) 656
melanoma - genetics (630) 630
male (615) 615
protein kinase inhibitors - pharmacology (603) 603
mice (582) 582
melanoma - pathology (567) 567
braf (544) 544
antineoplastic agents - therapeutic use (511) 511
protein kinase inhibitors - therapeutic use (461) 461
vemurafenib (456) 456
antineoplastic agents - pharmacology (450) 450
middle aged (434) 434
cell biology (417) 417
metastatic melanoma (375) 375
signal transduction (358) 358
aged (351) 351
skin neoplasms - drug therapy (349) 349
mutations (345) 345
article (342) 342
b-raf (340) 340
cell proliferation - drug effects (326) 326
biochemistry & molecular biology (323) 323
adult (319) 319
apoptosis (316) 316
signal transduction - drug effects (311) 311
sulfonamides - pharmacology (311) 311
tumors (311) 311
kinases (307) 307
indoles - pharmacology (303) 303
sulfonamides - therapeutic use (300) 300
activation (299) 299
research (299) 299
phosphorylation (298) 298
melanoma - metabolism (294) 294
care and treatment (290) 290
indoles - therapeutic use (285) 285
molecular targeted therapy (278) 278
resistance (270) 270
skin neoplasms - pathology (270) 270
metastasis (259) 259
apoptosis - drug effects (254) 254
xenograft model antitumor assays (254) 254
genetic aspects (253) 253
map kinase signaling system - drug effects (252) 252
survival (252) 252
treatment outcome (239) 239
expression (238) 238
pathway (237) 237
dermatology (235) 235
skin neoplasms - genetics (234) 234
neoplasms (233) 233
proteins (233) 233
drug resistance, neoplasm (225) 225
analysis (218) 218
acquired-resistance (215) 215
colorectal neoplasms - genetics (212) 212
antineoplastic combined chemotherapy protocols - therapeutic use (203) 203
ras proteins - genetics (202) 202
proto-oncogene proteins c-akt - metabolism (201) 201
melanoma - enzymology (198) 198
proto-oncogene proteins - genetics (198) 198
receptor, epidermal growth factor - antagonists & inhibitors (198) 198
dabrafenib (197) 197
drug resistance, neoplasm - genetics (197) 197
gene mutations (195) 195
colorectal neoplasms - drug therapy (191) 191
health aspects (191) 191
open-label (190) 190
extracellular signal-regulated map kinases - metabolism (188) 188
therapy (188) 188
neoplasms - drug therapy (181) 181
mitogen-activated protein kinase kinases - antagonists & inhibitors (180) 180
chemotherapy (178) 178
inhibition (177) 177
colorectal cancer (173) 173
cells (172) 172
aged, 80 and over (170) 170
cell proliferation (167) 167
mice, nude (166) 166
growth (165) 165
gene expression (163) 163
pharmacology & pharmacy (163) 163
neoplasm metastasis (160) 160
prognosis (159) 159
antibodies, monoclonal - therapeutic use (156) 156
targeted therapy (156) 156
proto-oncogene proteins p21 (154) 154
colorectal neoplasms - pathology (152) 152
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2670) 2670
French (30) 30
German (16) 16
Japanese (11) 11
Czech (5) 5
Russian (5) 5
Chinese (4) 4
Hungarian (2) 2
Spanish (2) 2
Swedish (2) 2
Croatian (1) 1
Danish (1) 1
Dutch (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 12/2010, Volume 468, Issue 7326, pp. 973 - 977
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2008, Volume 105, Issue 8, pp. 3041 - 3046
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 7, pp. 2750 - 2760
This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor PLX4720. Immunohistochemical staining of a tissue array covering all... 
METASTATIC MELANOMA | APOPTOSIS | PROTEIN | ONCOLOGY | PHOSPHORYLATION | CUTANEOUS MELANOMA | RAF KINASE | CANCER | MEDIATES RESISTANCE | LINES | ERK | RNA, Small Interfering - genetics | Up-Regulation | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins - biosynthesis | Bcl-2-Like Protein 11 | Melanoma - genetics | Apoptosis Regulatory Proteins - genetics | Indoles - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins B-raf - metabolism | Apoptosis Regulatory Proteins - biosynthesis | Melanoma - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | PTEN Phosphohydrolase - deficiency | Membrane Proteins - genetics | PTEN Phosphohydrolase - biosynthesis | Proto-Oncogene Proteins - genetics | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Membrane Proteins - biosynthesis | Membrane Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Apoptosis Regulatory Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Mutation | RNA, Small Interfering - administration & dosage | Index Medicus | PTEN | melanoma | BRAF | PLX4032 | therapy | resistance
Journal Article
Nature, ISSN 0028-0836, 09/2010, Volume 467, Issue 7315, pp. 596 - 599
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the... 
ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | MUTATION | KERATOACANTHOMAS | SENSITIVITY | SENESCENCE | SORAFENIB | HUMAN CANCER | PROGRESSION | BRAF(V600E) | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Macaca fascicularis | Melanoma - enzymology | Substrate Specificity | Positron-Emission Tomography | Extracellular Signal-Regulated MAP Kinases - metabolism | Indoles - administration & dosage | Neoplasm Metastasis | Melanoma - genetics | Phosphorylation - drug effects | Mutant Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Sulfonamides - chemistry | Mutant Proteins - genetics | Models, Molecular | Rats | Mutant Proteins - metabolism | Melanoma - pathology | Mutation - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Indoles - adverse effects | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Mutant Proteins - chemistry | Alleles | Dogs | Sulfonamides - adverse effects | Indoles - therapeutic use | Indoles - chemistry | Sulfonamides - administration & dosage | Control | Gene mutations | Melanoma | Development and progression | Genetic aspects | Research | Health aspects | Protein kinases | Cancer | Proteins | Mutation | Kinases | Rodents | Index Medicus | targeted therapy | melanoma | BRAF | PLX4032 | biomarker | oncogene
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 05/2017, Volume 132, pp. 63 - 76
B-Raf kinase is the key point in a main branch of mitogen-activated protein kinase pathways and some of its mutations, such as the V600E mutation, lead to the... 
Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Humans | Cell Line, Tumor | Mice
Journal Article
Nature, ISSN 0028-0836, 03/2010, Volume 464, Issue 7287, pp. 431 - 435
Activating mutations in KRAS and BRAF are found in more than 30% of all human tumours and 40% of melanoma, respectively, thus targeting this pathway could have... 
SELECTIVE INHIBITOR | POTENT | EFFICACY | PHOSPHORYLATION | MULTIDISCIPLINARY SCIENCES | IN-VIVO | C-RAF | HETERODIMERIZATION | B-RAF | PROTEIN-KINASE KINASE | CANCER | Neoplasms - metabolism | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Diphenylamine - pharmacology | raf Kinases - antagonists & inhibitors | Humans | Protein Multimerization | ras Proteins - metabolism | Protein Transport - drug effects | Extracellular Signal-Regulated MAP Kinases - metabolism | raf Kinases - metabolism | Diphenylamine - analogs & derivatives | Mitogen-Activated Protein Kinase Kinases - metabolism | Adenosine Triphosphate - metabolism | Indoles - pharmacology | Benzamides - pharmacology | Cell Membrane - metabolism | raf Kinases - genetics | Cell Membrane - drug effects | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Pyrazoles - pharmacology | Protein Structure, Tertiary | Proto-Oncogene Proteins - metabolism | Cell Line | Indenes - pharmacology | raf Kinases - chemistry | Proto-Oncogene Proteins c-raf - genetics | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Neoplasms - enzymology | Proto-Oncogene Proteins - genetics | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Proto-Oncogene Proteins c-raf - metabolism | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | MAP Kinase Signaling System - drug effects | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Proto-Oncogene Proteins c-raf - deficiency | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Neoplasms - pathology | Ras genes | Growth | Physiological aspects | Cellular signal transduction | Genetic aspects | Research | Mitogen-activated protein kinases | Competition | Clinical trials | Enzymes | Kinases | Index Medicus | Proteins | Cellular | Inhibitors | Pathways | Tumours | Signalling | Dimerization
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1877 - 1888
Journal Article